Florentine Hilbers
Florentine Hilbers
Breast International Group
Bestätigte E-Mail-Adresse bei bigagainstbc.org
Zitiert von
Zitiert von
Rare mutations in XRCC2 increase the risk of breast cancer
DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ...
The American Journal of Human Genetics 90 (4), 734-739, 2012
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles
FJ Gracia-Aznarez, V Fernandez, G Pita, P Peterlongo, O Dominguez, ...
PloS one 8 (2), e55681, 2013
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor
P Peterlongo, I Catucci, M Colombo, L Caleca, E Mucaki, M Bogliolo, ...
Human molecular genetics 24 (18), 5345-5355, 2015
Rare variants in XRCC2 as breast cancer susceptibility alleles
FS Hilbers, JT Wijnen, N Hoogerbrugge, JC Oosterwijk, MJ Collee, ...
Journal of medical genetics 49 (10), 618-620, 2012
The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?
FSM Hilbers, MPG Vreeswijk, CJ van Asperen, P Devilee
Clinical Genetics 84 (5), 407-414, 2013
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration
MC Southey, DJ Park, T Nguyen-Dumont, I Campbell, E Thompson, ...
Breast Cancer Research 15 (3), 1-2, 2013
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO …
M Lambertini, S Martel, C Campbell, S Guillaume, FS Hilbers, U Schuehly, ...
Cancer 125 (2), 307-316, 2019
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling
FS Hilbers, CM Meijers, JFJ Laros, M van Galen, N Hoogerbrugge, ...
PloS one 8 (1), e55734, 2013
Genetic variants in TGFβ-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer
FSM Hilbers, NB Boekel, AJ van den Broek, R van Hien, S Cornelissen, ...
Radiotherapy and Oncology 102 (1), 115-121, 2012
Breast Cancer Family Registry, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV …
DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ...
Am J Hum Genet 90 (4), 734-9, 2012
Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial
S Di Cosimo, V Appierto, S Pizzamiglio, P Tiberio, MV Iorio, F Hilbers, ...
Clinical Cancer Research 25 (13), 3887-3895, 2019
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families
IMM Lakeman, FS Hilbers, M Rodríguez-Girondo, A Lee, MPG Vreeswijk, ...
Journal of medical genetics 56 (9), 581-589, 2019
Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2
FS Hilbers, MS Luijsterburg, WW Wiegant, CM Meijers, M Völker‐Albert, ...
Human mutation 37 (9), 914-925, 2016
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
M Lambertini, C Campbell, RD Gelber, G Viale, A McCullough, F Hilbers, ...
Breast cancer research and treatment 177 (1), 103-114, 2019
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.
F Cardoso, L van't Veer, C Poncet, J Lopes Cardozo, S Delaloge, ...
Journal of Clinical Oncology 38 (15_suppl), 506-506, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
S Di Cosimo, V Appierto, S Pizzamiglio, M Silvestri, J Baselga, M Piccart, ...
International journal of molecular sciences 21 (4), 1386, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
D Eiger, NF Pondé, D Agbor-Tarh, A Moreno-Aspitia, M Piccart, ...
British journal of cancer 122 (10), 1453-1460, 2020
Serious adverse events among older patients in the ALTTO Trial
N Pondé, DA Tarh, L Korde, F Hilbers, C Jackisch, O Werner, R Gelber, ...
J Geriat Oncol 10 (6), S14-S15, 2019
152O First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)
PG Aftimos, AM Antunes De Melo e Oliveira, F Hilbers, D Venet, ...
Annals of Oncology 30 (Supplement_3), mdz100. 003, 2019
Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2 …
S Martel, M Lambertini, D Agbor-Tarh, N Falbel Ponde, A Gombos, ...
Journal of Clinical Oncology 36 (15_suppl), 10067-10067, 2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20